Keros Therapeutics, Inc. (KROS)

Several events have impacted Keros Therapeutics, Inc. (KROS) stock price in the past six months. The company announced a plan for the return of $375 million in excess capital on October 15, 2025, followed by an issuer tender offer on October 20, 2025, to repurchase up to $194.4 million of its common stock at $17.75 per share. On November 3, 2025, the company experienced a revision in its stock evaluation amidst market challenges. Keros Therapeutics reported its Third Quarter 2025 Financial Results on November 5, 2025, exceeding the consensus estimate for earnings per share. The preliminary and final results of the tender offer were announced on November 19 and November 20, 2025, respectively. In December 2025, the stock showed signs of market leadership, earning a 92 RS rating. On January 4, 2026, the stock price decreased by 3.3% following an analyst downgrade.

Keros Therapeutics, Inc.'s products and services do not exhibit traditional demand seasonality. The demand for its product candidates is driven by the progress of clinical trials, regulatory approvals, and the medical need for the conditions they aim to treat, rather than seasonal consumer patterns.

Keros Therapeutics, Inc. (KROS) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics for disorders related to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. KER-050 (elritercept) is being developed for low blood cell counts in myelodysplastic syndromes (MDS) and myelofibrosis. KER-012 (cibotercept) was under development for pulmonary arterial hypertension (PAH) and cardiovascular disorders, but the Phase 2 TROPOS trial was voluntarily halted due to pericardial effusion adverse events. KER-065 is being developed for obesity and neuromuscular diseases, initially focusing on Duchenne muscular dystrophy (DMD).

Keros Therapeutics, Inc. is headquartered in Lexington, Massachusetts, United States, with its primary operations and focus within the United States.

Keros Therapeutics' reputation has been influenced by the voluntary halting of the Phase 2 TROPOS trial for KER-012 due to safety concerns, which likely had a negative impact. The company has maintained analyst interest, with a consensus rating of "Hold". The company announced a formal review of strategic alternatives to maximize stockholder value. A significant stock price decline over the past year reflects negatively on its overall reputation.

Keros Therapeutics (KROS) has significant institutional ownership, including ADAR1 Capital Management, LLC, Vanguard Group Inc, and BlackRock, Inc. Alon Lazarus is a significant individual shareholder, owning 6.68% of the company's shares. Institutional shareholders hold approximately 71.56% to 79.60% of the stock, while insiders hold around 20.40% to 22.90%.